首页 > 专栏 > The Lancet The Lancet 共 79 条资讯 [Comment] Once-weekly oral antiretroviral therapy for HIV 2026-06-28 11:43:09 [Articles] Switch to once-weekly, single-tablet islatravir–lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial 2026-06-28 11:43:09 [Comment] Redefining therapy for previously treated renal cell carcinoma 2026-06-28 11:43:09 [Articles] Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial 2026-06-28 11:43:09 [Correspondence] The 2026 Kumamoto earthquake: rescue alone is not enough 2026-06-28 11:43:09 [Comment] Beyond a smoke-free generation: ending smoking within a generation 2026-06-28 11:43:09 [Comment] Pakistan and Afghanistan: a call for health diplomacy and restraint 2026-06-28 11:43:09 [Comment] New responses required to address rapidly changing needs: a Lancet Commission on adolescent health and wellbeing in China 2026-06-28 11:43:09 [Comment] Indonesia's health reform: from pandemic mandate to the six pillars of transformation 2026-06-28 11:43:09 [Comment] WHO's operational role in emergencies: mandate and evolution 2026-06-28 11:43:09 [Clinical Rounds] Massive bilateral perirenal infiltration in Erdheim-Chester disease 2026-06-28 11:43:09 [Perspectives] Embracing neurodiversity in medicine: insights from the history of psychiatry 2026-06-28 11:43:09 [Articles] Empirical treatment with valganciclovir in infants living with HIV and hospitalised with severe pneumonia in Africa: a multicentre, open-label, factorial, randomised, controlled, superiority trial 2026-06-28 11:43:09 [Comment] Intersectionality in climate and health equity research 2026-06-28 11:43:09 [Articles] Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial 2026-06-28 11:43:09 [Seminar] Psoriasis 2026-06-28 11:43:09 [Comment] A novel unimolecular GLP1 and amylin receptor agonist for glucose and weight control 2026-06-28 11:43:09 [Articles] Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial 2026-06-28 11:43:09 [Articles] Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial 2026-06-28 11:43:09 [Articles] Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial 2026-06-28 11:43:09 1234下一页 » 相关分类 The Lancet ScienceDirect Publication: The Lancet ScienceDirect Publication: The Lancet Oncology The Lancet Child & Adolescent Health The Lancet Diabetes & Endocrinology The Lancet Digital Health The Lancet Gastroenterology & Hepatology The Lancet Global Health The Lancet HIV The Lancet Haematology The Lancet Healthy Longevity The Lancet Infectious Diseases The Lancet Microbe The Lancet Neurology The Lancet Oncology The Lancet Planetary Health The Lancet Psychiatry